Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant SARS-CoV-2 (COVID-19) Envelope protein, GST, His Tag, 100µg  

Recombinant SARS-CoV-2 (COVID-19) Envelope protein, GST, His Tag, 100µg

Recombinant SARS-CoV-2 (COVID-19) Envelope protein,  AA Met 1 - Val 75, expressed from E. coli cells, GST, His Tag

Synonyms: Recombinant, protein, Envelope protein, Env polyprotein, Envelope glycoprotein, env, COVID-19

More details

ENN-C5128-100

Availability: within 7 days

455,00 €

Background
The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.

Source
Recombinant SARS-CoV-2 Envelope protein, GST,His Tag (ENN-C5128) is expressed from E.coli cells. It contains AA Met 1 - Val 75 (Accession # QHU79206.1).
Predicted N-terminus: Met

Molecular Characterization
This protein carries a GST tag at the N-terminus and a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 36.8 kDa. The protein migrates as 33-35 kDa under reducing (R) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 20 mM Tris, 5 mM EDTA, Arginine, pH8.0 with sucrose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Bioactivity
Please refer to product data sheet.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Identification of The Potential Matrix Protein of Invertebrate Iridescent Virus 6 (IIV6)"
Gencer, Yesilyurt, Ozsahin et al
J Invertebr Pathol (2023)
(2) "Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield"
Wrapp, Mu, Thakur et al
J Virol (2023)
(3) "Nuclear envelope morphology change upon repetitive treatment with modified antisense oligonucleotides targeting Hutchinson-Gilford Progeria Syndrome"
Abdelrahman, Nielsen, Stage et al
Biochem Biophys Rep (2023) 33, 101411
Showing 1-3 of 50782 papers.